Perspective 02

Why product validation must come before facility investment.

For an early-stage nutrition enterprise, a facility is not a strategy. It is a later decision that must follow evidence.

Dedicated infrastructure can signal seriousness, but it also creates capital, operating, regulatory, staffing, and utilization risk. The immediate question is whether a product and market pathway can be demonstrated responsibly.

Third-party capability can clarify the path.

Licensed processors, contract manufacturers, OEM partners, laboratories, logistics providers, and specialists can help evaluate manufacturability and delivery requirements before a business commits to dedicated assets. Each relationship still requires diligence on quality, roles, confidentiality, capacity, liability, and commercial terms.

Evidence should drive scale.

Before a controlled pilot, NBB needs clarity on buyer requirements, product specifications, qualified manufacturing capability, regulatory responsibilities, landed cost, payment security, and delivery conditions.

What this means for NBB.

NBB's current direction is to explore qualified third-party operating relationships. A dedicated facility would be considered only after technical, regulatory, commercial, financial, and market validation supports that decision.

Discuss a relevant requirement with NBB